Rodgers Brothers Inc. decreased its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 27.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 137,908 shares of the company's stock after selling 51,582 shares during the quarter. Rodgers Brothers Inc.'s holdings in Kenvue were worth $2,944,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the business. Handelsbanken Fonder AB boosted its stake in shares of Kenvue by 2.9% in the 4th quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company's stock valued at $15,846,000 after buying an additional 21,222 shares during the period. Alberta Investment Management Corp grew its holdings in Kenvue by 23.2% during the 4th quarter. Alberta Investment Management Corp now owns 582,895 shares of the company's stock worth $12,445,000 after acquiring an additional 109,700 shares in the last quarter. Longbow Finance SA increased its position in shares of Kenvue by 5.0% in the 4th quarter. Longbow Finance SA now owns 280,568 shares of the company's stock valued at $5,990,000 after purchasing an additional 13,287 shares during the last quarter. Steward Partners Investment Advisory LLC raised its holdings in shares of Kenvue by 143.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company's stock valued at $1,023,000 after purchasing an additional 28,216 shares in the last quarter. Finally, CORDA Investment Management LLC. lifted its position in shares of Kenvue by 1.4% during the 4th quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company's stock worth $26,754,000 after purchasing an additional 17,466 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Wall Street Analyst Weigh In
KVUE has been the subject of several recent analyst reports. Royal Bank of Canada restated a "sector perform" rating and set a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Barclays lifted their price target on shares of Kenvue from $21.00 to $23.00 and gave the stock an "equal weight" rating in a research note on Thursday, March 27th. Piper Sandler raised their price objective on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a report on Monday, February 24th. UBS Group reduced their target price on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Finally, Deutsche Bank Aktiengesellschaft downgraded Kenvue from a "buy" rating to a "hold" rating and dropped their price target for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $24.00.
Read Our Latest Research Report on KVUE
Kenvue Stock Performance
Shares of NYSE:KVUE traded down $0.23 during midday trading on Thursday, hitting $23.65. The stock had a trading volume of 21,693,496 shares, compared to its average volume of 16,761,110. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a 50 day moving average price of $22.50 and a two-hundred day moving average price of $22.47. The company has a market capitalization of $45.19 billion, a PE ratio of 44.61, a P/E/G ratio of 2.62 and a beta of 1.25.
Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.47%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue's payout ratio is 154.72%.
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
